Announced Fri, 24 Jul · 18:11 IST
Thyrocare resubmits Q1 FY27 results in machine-readable format
Compliance View source PDF
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹565.50
prior close
₹573.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.1+3.3+2.8+2.5——————————
Up moveDown movePending
AI summary
Thyrocare resubmitted Q1 FY27 results (quarter ended June 30, 2026) in machine-readable format per NSE request. Standalone revenue rose to Rs 225.66 cr from Rs 178.89 cr YoY, about 26 percent growth. Standalone PAT jumped to Rs 50.17 cr from Rs 36.05 cr YoY, with EPS of Rs 3.15. Consolidated revenue was Rs 240.02 cr and consolidated PAT was Rs 51.33 cr. Price Waterhouse gave an unmodified review conclusion. Board originally approved results on July 23, 2026.
Likely market impact
Strong YoY growth in revenue and profit signals healthy demand. Resubmission is procedural and does not alter fundamentals.